In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET
- PMID: 15695782
In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET
Abstract
2-(18)F-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine (2-(18)F-fluoro-A-85380) is a PET radioligand that is specific for nicotinic acetylcholine receptors (nAChRs) and has a high affinity for the alpha(4)beta(2) subtype. The purpose of this study was to evaluate different strategies to quantify 2-(18)F-fluoro-A-85380 binding in healthy nonsmoking human volunteers.
Methods: After intravenous injection of 189 +/- 30 MBq (0.8-5.7 nmol) of 2-(18)F-fluoro-A-85380, the first dynamic PET scan was acquired over 150 min. The second 30-min PET scan was performed 60 min later. Time-activity curves were generated from volumes of interest. 2-(18)F-Fluoro-A-85380 volume of distribution (DV) was quantified using compartmental kinetic analysis and Logan graphical analysis. In the kinetic analysis, the 1-tissue compartment model (1TCM) and the 2-tissue (2TCM) compartment model were applied. The most appropriate kinetic model was determined using the Akaike Information Criterion. The effect of reducing the PET study duration on the reliability of the DV values computed by the kinetic and the graphical analyses was evaluated.
Results: Time-activity curves were better described by the 2TCM. The DV values ranged from 5.2 +/- 0.5 in the occipital cortex, 6.2 +/- 0.2 in the frontal cortex, and 7.3 +/- 0.4 in the putamen to 15.4 +/- 2.1 in the thalamus. These regional DV values were consistent with the distribution of nAChRs in the human brain. Logan graphical analysis provided slightly lower DV values than those of the 2TCM (from -3.5% in the occipital cortex to -6.6% in the thalamus). The minimal study duration required to obtain stable DV estimates in all regions was similar for the 2 methods: 140 min for the 2TCM and 150 min for the Logan analysis. DV estimates obtained with the 2TCM were more stable than those calculated by the Logan approach for the same scan duration.
Conclusion: These results show that 2-(18)F-fluoro-A-85380 can be used to assess nAChRs binding in the human brain with PET.
Similar articles
-
Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET.Nucl Med Biol. 2005 Aug;32(6):585-91. doi: 10.1016/j.nucmedbio.2005.04.013. Nucl Med Biol. 2005. PMID: 16026705
-
Quantification of human nicotinic acetylcholine receptors with 123I-5IA SPECT.J Nucl Med. 2004 Sep;45(9):1458-70. J Nucl Med. 2004. PMID: 15347712 Clinical Trial.
-
First-in-human PET quantification study of cerebral α4β2* nicotinic acetylcholine receptors using the novel specific radioligand (-)-[(18)F]Flubatine.Neuroimage. 2015 Sep;118:199-208. doi: 10.1016/j.neuroimage.2015.05.065. Epub 2015 May 30. Neuroimage. 2015. PMID: 26037057
-
Central in vivo nicotinic acetylcholine receptor imaging agents for positron emission tomography (PET) and single photon emission computed tomography (SPECT).Biol Pharm Bull. 2009 Mar;32(3):337-40. doi: 10.1248/bpb.32.337. Biol Pharm Bull. 2009. PMID: 19252274 Review.
-
Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography.Life Sci. 2010 Apr 10;86(15-16):575-84. doi: 10.1016/j.lfs.2009.02.029. Epub 2009 Mar 18. Life Sci. 2010. PMID: 19303028 Free PMC article. Review.
Cited by
-
Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results.EJNMMI Phys. 2016 Dec;3(1):25. doi: 10.1186/s40658-016-0160-5. Epub 2016 Oct 21. EJNMMI Phys. 2016. PMID: 27770429 Free PMC article.
-
Brain imaging of nicotinic receptors in Alzheimer's disease.Int J Alzheimers Dis. 2010 Dec 28;2010:548913. doi: 10.4061/2010/548913. Int J Alzheimers Dis. 2010. PMID: 21253523 Free PMC article.
-
Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380.J Nucl Med. 2008 Oct;49(10):1628-35. doi: 10.2967/jnumed.108.050716. Epub 2008 Sep 15. J Nucl Med. 2008. PMID: 18794265 Free PMC article.
-
Evaluation of [(18)F]-(-)-norchlorofluorohomoepibatidine ([(18)F]-(-)-NCFHEB) as a PET radioligand to image the nicotinic acetylcholine receptors in non-human primates.Nucl Med Biol. 2015 Jun;42(6):570-7. doi: 10.1016/j.nucmedbio.2014.08.003. Epub 2014 Aug 8. Nucl Med Biol. 2015. PMID: 25858513 Free PMC article.
-
Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.Psychopharmacology (Berl). 2007 May;191(4):1005-14. doi: 10.1007/s00213-007-0725-z. Epub 2007 Feb 20. Psychopharmacology (Berl). 2007. PMID: 17310387 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources